PRNewsWire
03 Aug 2026, 06:22 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
MapLight Therapeutics' Phase 2 trial for its schizophrenia drug candidate failed to achieve statistical significance on the primary endpoint for the 330/6 mg dose. — Failure to meet primary endpoints in a Phase 2 trial is a critical setback for a biotech company's lead asset, directly impacting future revenue potential.
-0.90MapLight Therapeutics (MPLT) shares fell more than 50% in premarket trading and opened down 65% on July 27, 2026, following the trial results. — The massive price drop reflects a severe loss of market capitalization and investor confidence in the company's pipeline.
-0.60Law firm Schall, Brown & Schwartz LLP is investigating MapLight Therapeutics for potential violations of securities laws and misleading statements. — A fraud investigation and potential class-action litigation create additional legal liability and regulatory risk for the company.
-0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a fraud investigation and saw its share price crash after a drug candidate failed to achieve statistical significance in Phase 2 trials.
The company is mentioned as the subject of a fraud investigation by a shareholder rights litigation firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
